ADAG: Adagene Inc Price to Sales
Adagene develops anti-tumor antibodies while facing fierce competition and the risk of shifting therapeutic approaches. A lack of sales leaves the business dependent on external financing due to the uncertainty of early-stage testing. The current price-to-sales ratio demonstrates valuation volatility, with the value stabilizing at 14.50. Implementing laboratory robotics to accelerate molecule screening could become a key driver in increasing research efficiency.
Analytical breakdowns for Adagene (ADAG)
- stock price and consensus target price:
- market capitalization information:
- shareholders' equity book value data:
- debt obligations and liquidity statistics:
- company profitability and valuation multiples indicators:
ADAG - Net Profit|Projected Future Earnings Adagene|ADAG - P/E Multiple|Price to Future Earnings Ratio adagene.com|ADAG - PEG Multiple|EV/EBITDA Multiple Adagene Corp|ADAG - Operating profit EBITDA|Net earnings per share for the trailing year Adagene|ADAG - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months adagene.com|ADAG - Earnings growth in current year|Expected earnings per share trend next year Adagene
- issuer revenue and sales details:
General company analysis:ADAG - Adagene Inc
The P/S ratio determines the market value of a business relative to its generated revenue, measuring the premium for future growth. For Adagene (ADAG), the current P/S valuation reflects the monetization potential of its intellectual property and patents in the field of oncology antibodies. The dynamics of this indicator allow for an assessment of the efficiency of capitalizing future licensing payments. Analyzing this ratio helps investors avoid overpaying for assets at the peak of the market cycle.
Competitors of Adagene
argenx.com - Market Cap to Revenue Ratio|P/S Multiple BNTX (BioNTech)|Abivax Pharma (ABVX) - Price to Sales|ADMA Bio - P/S Multiple|PTGX - P/S Multiple|IMVT: P/S Multiple|Market Cap to Revenue Ratio KNSA|GRFS (Grifols) - P/S Multiple|P/S Multiple Adaptive Biotech|P/S Multiple CLDX|Aurinia Corp (AUPH) - Price-to-Revenue Multiple|P/S Multiple BCRX (BioCryst)|veratx.com (VERA) - Price to Sales|DNTH - Price-to-Revenue Ratio|PHVS (Pharvaris NV) - Market Cap to Revenue Ratio|ABCL: P/S Multiple|Price to Sales Tourmaline (TRML)|PGEN (Precigen, Inc.) - P/S Multiple|P/S Multiple pharming.com|P/S Multiple NKTR|Upstream Bio, Inc. - Market Cap to Revenue Ratio|P/S Multiple ZBIO (Zenas Biopharma, Inc.)|P/S Multiple Immunome Bio IMNM|Gossamer Bio, Inc. - P/S Multiple|Price-to-Revenue Multiple kalvista.com (KALV)|Septerna (SEPN) - Price-to-Revenue Ratio|Price-to-Sales Ratio PVLA (Pieris Pharma)|SVRA (Savara Corp) - P/S Multiple|RIGL: Market Capitalization-to-Revenue Ratio|P/S Multiple ANAB|P/S Multiple astriatx.com (ATXS)|Price-to-Revenue Ratio enGene ENGN|Market Capitalization-to-Revenue Ratio RAPT|JBIO - Price-to-Revenue Ratio|Aclaris Therapeutics, Inc (ACRS) - Market Cap to Revenue|KYTX: P/S Multiple|tizianalifesciences.com (TLSA) - P/S Multiple|Market Cap to Revenue CABA|VTYX: Market Capitalization-to-Revenue Ratio|P/S Multiple THTX|Price-to-Revenue Coefficient Avalo Therapeutics Inc|Price-to-Revenue Ratio Eledon Pharmaceuticals ELDN|AGEN - Market Cap to Revenue|CLYM - Price-to-Revenue Ratio|Zura Bio Ltd (ZURA) - Market Cap to Revenue|ATYR (aTyr) - Market Cap to Revenue|Ikena Oncology (IMA) - P/S Multiple|Price-to-Revenue Ratio Shattuck Labs Inc|Market Cap to Revenue Ratio EQ (Equillium Bio)|P/S Multiple CNTB|IMUX - Price to Sales|P/S Multiple ATRA (Atara Bio)|P/S Multiple InflaRx NV IFRX|X4 Pharmaceuticals - P/S Multiple|ACET (Adicet Bio) - Market Cap to Revenue Ratio|CELU: P/S Multiple|INmune Bio Inc (INMB) - P/S Multiple|BRNS (Barinthus Bio) - P/S Multiple|KZR - Price-to-Revenue Multiple|P/S Multiple SABS|AKTX - Price to Sales|Price-to-Revenue Ratio Enlivex Therapeutics Ltd. ENLV|QTTB: Market Cap to Revenue Ratio|GeoVax Labs Inc - P/S Multiple|Price to Sales Edesa Biotech Corp|IBIO: P/S Multiple|Carisma Therapeutics Inc. (CARM) - P/S Multiple|XTLB (XTL Biopharmaceuticals Ltd.) - P/S Multiple|Market Cap to Revenue Ratio BOLT (Bolt Bio)|P/S Multiple HCWB|P/S Multiple aptevotherapeutics.com (APVO)|P/S Multiple AIM (AIM ImmunoTech Inc.)|Price-to-Revenue Multiple Aditxt Inc.|GRI - Price-to-Revenue Ratio|Price-to-Sales Ratio XRTX|HIND: P/S Multiple|Revelation Biosciences Corp - Market Capitalization-to-Revenue Ratio|INDP (Indaptus Therapeutics) - P/S Multiple|P/S Multiple scinai.com|Price-to-Revenue Ratio CalciMedica, Inc. (CALI)|AFMD (affimed.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Allakos ALLK|HOOK - Market Cap to Revenue|IGM Bio - P/S Multiple|ITOS - P/S Multiple|OCEA (Ocean Biomedical) - Market Cap to Revenue|TC BioPharm (Holdings) Plc - Market Capitalization-to-Revenue Ratio|THRD (Third Harmonic Bio, Inc) - P/S Multiple
